Generic Name and Formulations:
Lipid 20% (Intralipid 20%) emulsion (soybean oil 3.5g), dextrose anhydrous 6.8g, amino acids 2.36g, total nitrogen 375mg, electrolytes (sodium acetate 170mg, potassium chloride 124mg, sodium glycerophosphate 105mg, magnesium sulfate 68mg, calcium chloride 20mg); per 100mL; for IV infusion after mixed; contains aluminum.
Fresenius Kabi USA
Indications for PERIKABIVEN:
To provide a source of calories, protein, electrolytes, and essential fatty acids in adults requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. May be used to prevent essential fatty acid deficiency or treat negative nitrogen balance.
Individualize. Dose based on patient’s clinical condition, body wt, nutritional/fluid requirements, and additional energy given orally/enterally. Administer by IV infusion via a peripheral or central vein. Usual dose: 27–40mL/kg/day; max: 40mL/kg/day. Max infusion rate: 3.7mL/kg/hr. Usual infusion duration: 12–24 hours; may continue treatment based on patient’s clinical condition. If serum triglycerides (>400mg/dL): interrupt infusion and monitor serum triglycerides; restart at a lower rate once triglycerides are <400mg/dL; increase in smaller increments and check levels before each adjustment. Renal impairment: may adjust dose based on protein requirements; see full labeling.
<2yrs: not recommended.
Egg, soybean, peanut, corn or corn product allergy. Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1000mg/dL). Inborn error of amino acid metabolism. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, MI, acidosis, hemodynamic instability requiring significant vasopressor support). Hemophagocytic syndrome.
Risk of deaths in preterm and low birth weight infants: see full labeling. Correct severe fluid, electrolyte and acid-base disorders prior to initiating. Measure serum triglycerides at baseline, with each dose increase, and regularly during therapy. Discontinue and treat if hypersensitivity reactions occur. Monitor for signs/symptoms of infection and essential fatty acid deficiency (EFAD). Severely undernourished: avoid overfeeding. Diabetes or hyperglycemia. Heart failure or pulmonary edema; monitor fluid status closely. Risk of Parenteral Nutrition Associated Liver Disease (PNALD); consider discontinuation or dose reduction if abnormal LFTs occur. Monitor fluids, electrolytes, serum osmolarity, blood glucose, liver and kidney function, ammonia levels, CBCs, platelets, coagulation parameters, and overall energy intake throughout treatment. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
Vitamin K content may antagonize anticoagulants (eg, coumarin, warfarin); monitor. Avoid simultaneous co-administration with ceftriaxone; precipitation can occur. High lipid levels in plasma may interfere with blood tests (eg, hemoglobin, triglycerides, bilirubin, LDH, oxygen saturation).
Macronutrients + electrolytes.
Hyperglycemia, hypokalemia, pyrexia, hypertriglyceridemia; hyperosmolar syndrome, refeeding syndrome, thrombophlebitis, hepatobiliary disorders, hyperammonemia, PNALD, aluminum toxicity (esp. preterm infants, renal impairment); rare: fat overload syndrome.
Emulsion (1440mL, 1920mL, 2400mL)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|